Table 1.
Characteristic and outcomes of all enrolled patients
| ID | Age | Sex | Diagnosis | Number of prior treatments | Dose level | Best response | NK cell increase (fold) | CD8+ T-cell increase (fold) |
|---|---|---|---|---|---|---|---|---|
| 1 | 37 | Female | ATL-a | 7 | 1 | SD | 1.04 | 1.41 |
| 2 | 18 | Male | ATL-a | 1 | 1 | CR | 2.81 | 1.21 |
| 3 | 20 | Male | ATL-a | 2∗ | 1 | PD | 5.93 | 2.92 |
| 4 | 48 | Male | ATL-a | 1 | 2 | PD | 5.22 | 3.57 |
| 5 | 66 | Male | ATL-a | 3 | 2 | SD | 11.51 | 4.88 |
| 6 | 41 | Male | ATL-c | 2 | 2 | PR | 10.94 | 3.24 |
| 7 | 71 | Female | PTCL-NOS | 6 | 2 | PD | 8.43 | 0.97 |
| 8 | 51 | Male | PTCL-NOS | 4∗ | 3 | CR | 4.40 | 2.15 |
| 9 | 48 | Male | ATL-c | 1 | 3 | PR | 15.31 | 1.95 |
| 10 | 46 | Male | ATL-a | 1 | 3 | PD | — | — |
| 11 | 43 | Male | ATL-a | 1 | 3 | SD | 17.12 | 5.98 |
ATL-a, acute subtype adult T-cell leukemia/lymphoma; ATL-c, chronic subtype adult T-cell leukemia/lymphoma; PD, progressive disease; SD, stable disease.
∗
Prior treatment includes allogeneic stem cell transplantation.